Should I Take a Biologic? Will It Work for Me?
Evidence-based answers to help you have an informed conversation with your prescriber about starting biologic therapy.
If your autoimmune condition is moderate to severe and hasn't responded adequately to conventional treatments, a biologic may significantly improve your quality of life. Most patients experience meaningful improvement within 8–12 weeks. Call BiologicHealthPlus at +1 929 628 4081 to verify your insurance coverage before your next prescriber appointment.
Patient Questions: Should I / Will Biologics...?
Will biologics help psoriasis?
Yes. Biologics are among the most effective treatments available for moderate-to-severe plaque psoriasis. IL-23 inhibitors like Skyrizi and Tremfya achieve clear or almost-clear skin (PASI 90) in 75–85% of patients in clinical trials.
Will biologics help with pain?
Yes. Biologics reduce inflammation, which is the source of pain in conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Most patients report significant pain reduction within the first 8–12 weeks of treatment.
Will biologics get cheaper?
Biosimilar versions of many biologics (e.g., adalimumab biosimilars for Humira) are entering the market and driving down costs. Additionally, manufacturer copay programs and patient assistance programs through BiologicHealthPlus already reduce costs to $0–$35/month for most patients.
Should I take a biologic for psoriasis?
If your psoriasis covers more than 10% of your body surface area, affects your quality of life, or involves sensitive areas like the scalp, nails, or joints, your dermatologist may recommend a biologic. Biologics provide sustained, targeted relief that creams and light therapy cannot.
Should biologics be stopped before surgery?
Most guidelines recommend stopping biologics 1–5 half-lives before elective surgery to reduce infection risk. The exact timing depends on the specific biologic and surgical procedure. Never stop your biologic without discussing with both your prescriber and surgeon.
Should I avoid biologics?
You should discuss biologic risks with your prescriber. Biologics may not be appropriate if you have active serious infections, untreated latent TB, or certain cancers. Your prescriber screens for all contraindications before prescribing.
Will biologics kill me?
Biologics are FDA-approved medications with defined safety profiles. Serious adverse events are rare. The FDA requires extensive clinical trial data before approval and monitors post-market safety continuously. Your prescriber weighs all risks against your disease burden.
Do biologics work for everyone?
No. Approximately 30–50% of patients achieve the primary clinical endpoint in initial trials, and some patients lose response over time. When one biologic stops working, switching to a different mechanism often restores response.
When do biologics stop working?
Some patients experience secondary loss of response over months or years, often due to antibody development. Signs include returning symptoms despite continued dosing. Your prescriber may increase frequency, add methotrexate, or switch to a different biologic class.
Why are biologics so expensive?
Biologics are expensive because they are produced using complex living cell systems, require extensive clinical testing, need cold-chain storage throughout manufacturing and distribution, and target rare or complex diseases with limited patient populations.
Have a question about your biologic?
Speak with a BiologicHealthPlus pharmacist 24/7Detailed Answers
Yes. Biologics are among the most effective treatments available for moderate-to-severe plaque psoriasis. IL-23 inhibitors like Skyrizi and Tremfya achieve clear or almost-clear skin (PASI 90) in 75–85% of patients in clinical trials.
Yes. Biologics reduce inflammation, which is the source of pain in conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Most patients report significant pain reduction within the first 8–12 weeks of treatment.
Biosimilar versions of many biologics (e.g., adalimumab biosimilars for Humira) are entering the market and driving down costs. Additionally, manufacturer copay programs and patient assistance programs through BiologicHealthPlus already reduce costs to $0–$35/month for most patients.
If your psoriasis covers more than 10% of your body surface area, affects your quality of life, or involves sensitive areas like the scalp, nails, or joints, your dermatologist may recommend a biologic. Biologics provide sustained, targeted relief that creams and light therapy cannot.
Most guidelines recommend stopping biologics 1–5 half-lives before elective surgery to reduce infection risk. The exact timing depends on the specific biologic and surgical procedure. Never stop your biologic without discussing with both your prescriber and surgeon.
You should discuss biologic risks with your prescriber. Biologics may not be appropriate if you have active serious infections, untreated latent TB, or certain cancers. Your prescriber screens for all contraindications before prescribing.
Biologics are FDA-approved medications with defined safety profiles. Serious adverse events are rare. The FDA requires extensive clinical trial data before approval and monitors post-market safety continuously. Your prescriber weighs all risks against your disease burden.
No. Approximately 30–50% of patients achieve the primary clinical endpoint in initial trials, and some patients lose response over time. When one biologic stops working, switching to a different mechanism often restores response.
Some patients experience secondary loss of response over months or years, often due to antibody development. Signs include returning symptoms despite continued dosing. Your prescriber may increase frequency, add methotrexate, or switch to a different biologic class.
Biologics are expensive because they are produced using complex living cell systems, require extensive clinical testing, need cold-chain storage throughout manufacturing and distribution, and target rare or complex diseases with limited patient populations.